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ABSTRACT 
 
Oral manifestations of Human Immunodeficiency Virus (HIV) are common, although since 
the introduction of HAART, a decline in opportunistic infections has been observed. This 
decline is more evident in resource-rich than poorly resourced countries. Aids-Defining-
Cancer (ADC) cases have also declined in resource-rich countries; however there has been a 
sharp increase in Non-Aids-Defining-Cancer (NADC) cases.  
Aim: The study was to profile and characterize head and neck cancers (HNCs) among HIV- 
positive cases diagnosed in the Department of Oral Pathology, WOHC, from 2009 – 2013. 
Methods: This was a records-based retrospective descriptive study with an analytic 
component. Archived records from the Department of Oral Pathology were reviewed. HIV 
serology results as well as CD4+T-cell counts and the viral load were verified from NHLS’s 
archived records.  
Results: A total of 1605 cases of HNC were recorded, of which 389 (24.2%) were HIV- 
positive. The mean age of the patient sample was 51.7 ± 16.4 years. Of the 389 confirmed 
HIV-positive cases, 52.3% were females and 47.7% were males. Univariate multinomial 
regression analysis of the morphological type of cancer showed that the likelihood of patients 
with HIV infection to be diagnosed with KS and NHL, was significantly greater at 35.7% and 
34.2% respectively with a p value =  0.00, compared to any other cancer type. Oral squamous 
cell carcinoma was not found to be an ADC. 
Conclusion: Within the period 2003 – 2009 ADCs still frequently occurred amongst HIV- 
positive people in South Africa, despite HAART being made accessible at state health 
institutions since 2004.  
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
The human immunodeficiency virus (HIV) is a RNA retrovirus belonging to the lentivirus 
subfamily.  It is the virus that causes HIV infection. The virus first isolated by Barre et al. in 
Paris and Popovic et al. in 1983 in the USA, still remains as a huge threat to humanity to 
date. Since its discovery, HIV has spread at an alarming rate, more so in the resource-poor 
countries compared to the resource-rich countries. Two forms of the virus have been isolated, 
HIV-1 and HIV-2 (Barreʹ-Sinoussi et al, 1983). The two strains are related but genetically 
different. HIV-1 infection was mainly endemic in Central as well as East Africa and is now 
considered as pandemic in this region and has also spread to the Western countries.  HIV-2 is 
mostly found in West Africa and leads to a ‘milder’ infection than the HIV-1 strain. HIV is 
acquired mainly via sexual routes, unsterilized drug injections among drug users, infected 
blood transfusions or during organ transplant procedures and mother-to-child transmission 
during birth or breastfeeding. HIV has an affinity for cells presenting receptors for T 
lymphocytes (CD4+T-cells) of the immune system in the body and will attach itself to these 
receptors, thus damaging the immune system and ultimately causing disease in an infected 
individual (Scully, 2013).  The most advanced stage of HIV infection is acquired immuno-
deficiency syndrome (AIDS).  AIDS is diagnosed when an individual(s) have a CD4+ count 
of <200 cells/mm³ and they begin experiencing opportunistic infections because of the 
suppressed immune system (CDC, 1993).  
In South Africa the estimated number of people living with HIV was estimated at 6. 4 million 
during 2013 with 500 000 of them being new infections (UNAIDS; HIV and AIDS estimates, 
2014). In 2015 this figure had increased to 7 million, with prevalence rate of 19.2% in adults 
aged 15 – 49 years (UNAIDS, 2015). The epidemic is particularly more severe in Sub-
Saharan Africa and Asia. Women between the ages of 15 and over, make up 4 million (57%) 
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of the estimated number of people infected with HIV in South Africa (UNAIDS, 2015). 
AIDS still remains the number one cause of deaths in Africa and the second among young 
people globally (UNAIDS, 2015). The number of people who died from HIV-related illnesses 
in South Africa during 2015 was 162,445, which make up almost a third (30, 5%) of all 
deaths in the country (UNAIDS, 2015). This is despite an aggressive campaign by 
government institutions to educate the public about this deadly virus and highlighting the 
preventative measures that can be adopted to stop the spread and number of new infections. 
Free testing has and is still offered at state health institutions nationally as well as the roll-out 
of highly active anti-retroviral therapy (HAART) since April 2004 to people infected with the 
virus with CD4+cell counts <200 cells/mm³, and more recently to all that test positive. 
Despite all of these measures, more than half (51%) of the people infected with HIV in South 
Africa do not know of their HIV status (SA stats, 2015). It has been suggested that the main 
reason behind the unsuccessful prevention and diagnosis of HIV is probably the stigma and 
discrimination towards people living with HIV by the society, more so among the uneducated 
and those from low socio-economic backgrounds (Simbayi et al, 2007; Airhihenbuwa et al, 
2009). 
Oral lesions are a common finding in people infected with HIV (Narani et al, 2001). They are 
often the presenting feature, and may predict a deteriorating immune system and a poor 
prognosis for the individual (Narani et al, 2001). They also predict HIV infection (Shangase 
et al, 2004) and progression of HIV disease to AIDS (Coogan et al, 2005). Cancer is another 
significant cause of morbidity and mortality in people infected with HIV, and is one of the 
recognised manifestations of the infection and progression of the individual to AIDS stage 
(Newcomb-Fernandez, 2003). The two strains of HIV (HIV-1 and HIV-2) are not directly 
oncogenic. Robin Weiss (2001) stated that these viruses “can indirectly cause AIDS-defining 
cancer (ADCs) by allowing the DNA viruses underlying these tumours to exert their 
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oncogenic effects in the immunosuppressed host”. This means that on their own the viruses 
are not oncogenic, but need the presence of other multiple factors in the particular 
immunosuppressed host to result in cancer (Qadir et al, 2016).  The incidence of cancer in 
people infected with HIV is therefore highly increased when compared with the general 
population (D’Souza et al, 2014).  
There are established cancers that affect people infected with HIV and these are referred to as 
AIDS-defining cancers (ADCs) by the Centres for Disease Control (CDC), and they are 
Kaposi sarcoma (KS), Non-Hodgkin’s Lymphoma (NHL) and invasive cervical cancer (ICC). 
There are however, other types of cancer that appear among HIV-infected people more than 
the general population and they are referred to as non-AIDS-defining cancers (NADCs), and 
they are anal, lung, liver , kidney and testicular cancers as well as Hodgkin’s lymphoma (HL) 
and some head and neck cancers (Barbaro et al, 2007; Silverberg et al, 2009; Deeken et al, 
2012). These are cancers that were previously not associated with HIV infection. However, 
studies conducted mainly in resource-rich countries have demonstrated an increased 
incidence of NADCs among HIV-infected individuals (Engels et al, 2008).   
Head and neck cancers (HNC) make up 5 – 50% of all cancers diagnosed worldwide 
(Garfinkel L, 1995). Gilyoma et al, (2015) stated that 650,000 new cases of HNC are 
currently being diagnosed worldwide with an increasing incidence in resource-poor countries. 
The management of these tumours is complex and requires a multidisciplinary approach. 
(Licitra et al, 2009).  HNCs are an important cause of morbidity and mortality as they affect 
organs that are responsible for vital functions in the body e.g. oral cavity, pharynx, larynx, 
nose and lymph nodes (Amusa et al, 2004; Fan CY, 2004; Gilyoma et al, 2015). The reasons 
cited for this increased morbidity and mortality are the varied nature of histological patterns 
seen in this anatomical region, and individuals presenting themselves to health facilities for 
treatment once the cancer is already at an advanced stage making successful treatment of 
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these tumours difficult (Nwawolo et al, 2001,  Amusa et al, 2004, Licitra et al, 2009). It is 
therefore important for dental professionals to recognize and diagnose these lesions early in 
order to improve the treatment outcomes. 
In the head and neck region ADCs include Kaposi sarcoma (KS) and non-Hodgkin’s 
lymphoma (NHL). In the European Community Clearinghouse (ECC) Classification on Oral 
Problems Related to HIV Infection (1993), Kaposi sarcoma and non-Hodgkin’s lymphoma 
fall into a group of neoplastic lesions strongly associated with HIV including oral squamous 
cell carcinoma (OSCC). In 2009, Shiboski et al updated the existing classification and 
organized case definitions according to their aetiology with OSCC, NHL and KS falling 
under neoplasms associated with HIV. Whether KS is just a benign angioproliferative 
disorder or a true malignancy owing to the oncogenic nature of the causative factor, the 
human herpes virus-8 (HHV-8), is still not clearly understood and remains a contentious topic 
(Feller et al, 2007). For the purposes of this current study, KS will be regarded as a cancer. 
Even though OSCC appears under lesions that are strongly associated with HIV infection, it 
is not regarded as an ADC. This is because the risk factors for the development of OSCC in 
HIV- positive people are the same as those for the general population (tobacco, alcohol and 
human papilloma virus (HPV) infection), and is therefore regarded as a NADC. Recently 
HIV- positive people have been found to have an increased prevalence of oral human 
papilloma virus (HPV) infection (about 2-fold) and HNC (about 2.3-fold) (Beachler et al, 
2012). Unsafe sexual behaviour is thought to be the risk factor for this sharp increase 
(Pytynia et al, 2014, D’Souza et al, 2014). McLemore et al (2010) reported laryngeal cancer 
as the most common malignancy followed by oropharyngeal cancer in the USA particularly 
in HIV-positive individuals. HPV-16 positive oropharyngeal cancer cases are so much on the 
rise in the USA that they have been referred to as epidemic, especially among middle aged 
white males who are non-smokers but have multiple sexual partners (Pytynia et al, 2014, 
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D’Souza et al, 2014). The reasons for the development of OSCC in HIV-positive people 
remains unclear but several mechanisms are thought to be contributing factors. The 
immunocompromised state of HIV- positive patients is one of the mechanisms thought to 
assist in the faster progression of HPV (an oncogenic virus) infection to carcinogenesis 
because of an imbalance between cellular proliferation and differentiation that occurs 
(Pytynia et al, 2014, D’Souza et al, 2014). D’Souza et al, (2014) stated that in HIV- positive 
people it is not clear which one of the reasons mentioned increase the risk of cancer more 
than the other.  
A decline in opportunistic infections including oral lesions and ADCs has been observed in 
resource-rich countries since the introduction of antiretroviral therapy (Engels EA, 2009, 
Cobucci et al, 2014).  The same statement however, cannot be said for poorly resourced 
countries where the incidence of ADCs is still high (Stein et al, 2008, Sasco et al, 2010, 
Mbulaiteye et al, 2011, Casper, 2011). Previously NADCs were not associated with HIV 
infection. However, studies conducted mainly in resource-rich countries have demonstrated 
an increased incidence of NADCs among HIV-infected individuals (Engels et al, 2008).  In 
the pre- HAART era, NADCs accounted for only 38% of all cancers compared with 58% of 
all cancers post-HAART era in the United States (Deeken et al, 2012). HAART has resulted 
in HIV- infected people living longer than before, leading to a growing cancer burden 
(Engels et al, 2008, Engsig et al, 2011, Deeken et al, 2012). A higher prevalence of virus-
related infections, smoking or alcohol intake as well as risky sexual behavior among HIV 
infected people also elevates the risk for NADCs more than for the general population (40-
60% vs. 17%) (Engels et al, 2008, Baker et al, 2008, Silverberg et al, 2011). Studies 
conducted here in sub-Saharan-Africa on HNCs among HIV- positive people are few, making 
it difficult for one to draw the same conclusions about ADCs and NADCs as has been done in 
Europe and America. Casper (2011) reported that the impact of HIV in Africa is slightly 
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different than that observed in the Western countries, owing to the fact that most infections 
seen in these resource-poor settings are due to oncogenic viruses and environmental exposure 
to carcinogens in the general population as well as delayed access to HAART for HIV-
infected individuals. Mbulaiteye et al, (2011) also stated that the HIV impact in this region 
may be different compared with that experienced in the Western countries because infections 
with oncogenic viruses account for most of the cancers observed in sub-Saharan Africa. 
Limited data have been collected since the introduction of HAART in resource-poor 
countries to determine the impact it has had on ADCs (Parkin et al, 2010). Data from Uganda 
cancer registry showed that there has been an increase in the number of ADCs seen in this 
region instead of a decrease (Parkin et al, 2010). Sitas et al, (2008) also reported high 
numbers of KS and NHL in HIV- infected people in a study conducted in Johannesburg, 
South Africa. Another study conducted in Uganda found that ADCs had an increased risk of 
still developing in HIV-infected patients, with few cases of NADCs recorded in this region 
(Mbulaiteye et al, 2006). Nwaorgu et al, (2007) reported the larynx as the most common 
anatomical site for HNC diagnosis (31, 3%), followed by the salivary glands in a study 
conducted in sub-Saharan Africa. Amusa et al, (2005) reported different results in a study she 
conducted in Nigeria where the oral cavity was the most common site for HNCs followed by 
the neck, thyroid and oesophagus. The least affected sites in Amusa’s study were the ears and 
paranasal sinuses. Stein et al (2008) reported similar results in South Africa as other studies 
conducted in Africa. He found a 50-fold higher risk for developing KS and HNL (ADCs) in 
HIV- positive people. The risk for NADCs, like Hodgkin’s lymphoma (HL) and anogenital 
cancer, was 1.5 – 2.5 times higher. HAART roll out to the public by government institutions 
in South Africa was initiated only in April 2004 (Simelela et al, 2014). Before the roll-out in 
South Africa, only people who could afford to purchase antiretroviral medication from 
private institutions were on HAART. Between 1997 and 2004, death rates increased >5-fold 
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for young women and doubled for middle-aged males in South Africa (Stein et al, 2008). 
HAART therefore, clearly plays an important role in the types of cancers and incidence rates 
observed among HIV-positive patients between resource-rich and resource-poor countries. 
Sitas et al, (2000) and Stein et al, (2008) noted this fact as one possible reason for the 
differences observed too. 
Successful treatment of the virus has remained elusive with no effective control or prevention 
of new infections, resulting in an increased number of deaths among HIV- infected 
individuals as a result of opportunistic infections. Recent progress in the development of an 
effective HIV vaccine however, provides new hope for future eradication and prevention of 
new infections (Stephenson et al, 2016). 
 
The aim of this study therefore, was to identify and characterise the type and number of 
HNCs diagnosed histologically in HIV-positive patients in the Department of Oral Pathology, 
Wits Oral health Centre (WOHC), from 2009 – 2013. This was a period after the roll-out of 
HAART to people infected with HIV and CD4+T-cell counts of <200 cells/mm³ by 
government institutions in SA. We hope that the results will assist in determining whether 
there was a significant change in the type of HNC cases diagnosed among HIV-infected 
individuals. This will also confirm whether these HNCs are ADCs or NADCs.  
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CHAPTER 2: AIM AND OBJECTIVES 
 
The aim of this study therefore, was to identify and characterise the type and number of 
HNCs diagnosed histologically in HIV-positive patients in the Department of Oral Pathology, 
Wits Oral health Centre (WOHC), from 2009 – 2013. 
The objectives of the study were to: 
1. Identify head and neck cancers (HNCs) occurring among HIV-positive patients 
diagnosed in the  Department of Oral Pathology from 2009 to 2013 
2. Determine the most common HNCs occurring among HIV-positive patients 
3. Determine the site predilection of HNCs among HIV-positive patients 
4. Assess the association between the presence of the HNCs and the  immune status of 
the HIV-positive patient (CD4+T-cell count and the level of infection (viral load)) 
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CHAPTER 3: METHODOLOGY 
 
3.1    Study design 
This was a records-based retrospective descriptive study with an analytical component, 
conducted at the Oral Pathology Department, WOHC. 
  
3.2   Study population and sample 
 
The study population consisted of all histologically diagnosed cases of HNC in the Oral 
Pathology Department’s archives from January 2009 – December 2013. A total sample size 
of 1605 HNC cases was recorded. Confirmation of HIV seropositivity for the subjects was 
obtained from records of the National Health Laboratory Services (NHLS) of South Africa.   
 
3.3   Data and Statistical analysis 
 
Data analysis was done using the IBM SPSS 23.0. Descriptive statistics of measurement of 
central tendencies was used to determine the frequency, mean and standard deviation. 
Inferential statistics of binary and multinomial logistic regression were used to determine the 
association between the independent variables (age, gender and HIV status) and the 
dependent variable (cancer diagnosis or type). Since the study sample size was already 
determined from the retrospective nature of the study, power calculations were done to 
minimize type 2 errors when making comparisons. Statistical significance was inferred at p < 
0.05 for all analyses. 
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3.3.1 Independent variables 
 
The age, gender and HIV status of all the cases recorded were noted as independent variables 
 
3.3.2 Dependent variable 
 
The histological diagnosis of head and neck cancer or type of head and neck cancer in HIV- 
positive cases, was noted as a dependent variable 
 
3.3.3 Analysis by objective 
 
Table 1: Data analysis by specific objectives 
Objectives  Data analysis  
Identify head and neck cancers occurring 
among HIV-positive cases presenting at 
WOHC, from 2009 to 2013 
- Identify the diagnosed head and 
neck cancer 
- Identify the site of head and neck 
cancer 
Central tendencies of frequency were used 
to identify the diagnosis and the site of head 
and neck cancers. 
Determine the  association between the 
presence of the HNCs and the immune 
status 
Univariate and multivariate multinomial 
regression was used to determine the 
association between the diagnosis of head 
and neck cancer  
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3.4 Ethical considerations 
 
Permission to undertake the current study was granted by the University of the 
Witwatersrand’s Human Research Ethics Committee – (Medical - Ethics clearance certificate 
number: M140655, see Appendix B). Permission to access histological patient records was 
sought and granted by the Department of Oral Pathology, WOHC, (see Appendix C). The 
NHLS also granted permission to access and confirm the blood results for all the cases 
identified and included in the study (see Appendix D and E). All cases recorded were 
allocated a reference number for protection of their identity.   
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CHAPTER 4: RESULTS 
4.1: Demographic characteristics of the cohort 
 
A total of 1605 cases of head and neck cancer were recorded at the Oral pathology 
department, WOHC, between 2009 and 2013. The demographic characteristics of the cases 
are outlined in Table 2 below.  
Only 389 (24.2%) of the cases were confirmed HIV- positive. Of the remaining 1216 cases, 
229 (14.3%) were confirmed HIV- negative and 987 (61.5%) were unknown/unconfirmed 
cases. The mean age of all the subjects recorded was 51.7 ± 16.4 years. For the confirmed 
HIV- positive cases, the mean age was 51.7 ± 16.4 years with 46.1% of them in the 36 – 55 
years age group. For confirmed HIV- negative patients, the mean age was 52.1±16.9 and for 
unconfirmed/unknown group the mean age was 51.6±16.1. More females (52.3%) than males 
(47.7%) were HIV- positive. HIV- infection was noted more among black patients (91.5%). 
Only 5.9% and 1.0% of Coloured and Caucasians patients respectively were confirmed HIV-
positive cases. The ethnicity of 1.5% confirmed HIV-positive cases remained unknown. 
Alcohol use and smoking were mainly unknown in this cohort, 97.6% for alcohol and 79.4% 
for smoking respectively. Among the HIV-positive cases, only 5.4% were known smokers 
and only 0.8% had a confirmed history of alcohol use. Some of the HIV-positive people were 
already receiving HAART (19.0%) with many unconfirmed cases (80.5%) because of 
missing information. Only 31.9% (< 200 cells/mm³) and 20.1% (> 200 cells/mm³) HIV-
positive cases had confirmed CD4+T-cell count results available, even after an extensive 
search from the NHLS archived records. Detectable RNA viral load was confirmed in 27.2% 
of the HIV-positive subjects with 71.5% remaining unknown. Only 1.3% of HIV-infected 
subjects had undetectable RNA viral load after being tested.  
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Table 2: Demographic characteristics of patients with head and neck cancer between 2009 
and 2013 at WOHC 
Variables HIV+ 
(n=389) 
HIV- 
(n=229) 
Unknown 
(n=987) 
p-value Total 
(N=1605) 
Mean age  ± 
SD* 
38.4 ± 11.0 55.4 ± 15.0 56.1 ± 15.6  0.00 51.7 ± 16.4 
Age group* n 
(%) 
   0.99  
≤ 35 years 71 (24.1) 45 (15.3) 179 (60.6) 295 (18.6) 
36-45 years 63 (24.1) 33 (12.6) 165 (63.3) 261 (16.5) 
46-55 years 
56-65 years               
82 (25) 
88 (22.6) 
47 (14.3) 
56 (14.4) 
199 (60.7) 
245 (63) 
328 (20.7) 
389 (24.6) 
≥ 66 years 77 (24.8) 46 (14.7) 188 (60.5) 311 (19.6) 
Gender* n (%)    0.00  
Male 185 (47.7) 81 (35.4) 344 (34.9) 628 (39.2) 
Female 203 (52.3) 148 (64.6) 643 (65.1) 976 (60.8) 
Ethnicity* n 
(%) 
   0.00  
African 356 (91.5) 140 (61.1) 635 (64.5) 1131 (70.6) 
Caucasian 4 (1.0) 3 (1.3) 34 (3.5) 41 (2.6) 
Indian - 6 (2.6) 20 (2.0) 26 (1.6) 
Mixed 23 (5.9) 74 (32.3) 273 (27.7) 370 (23.1) 
Unknown 6 (1.5) 6 (2.6) 23 (2.3) 35 (2.2) 
Alcohol, n (%)    0.00  
Yes 3 (0.8) 6 (2.6) 23 (2.3) 32 (2.0) 
No 2 (0.5) - 5 (0.5) 7 (0.4) 
Unknown 384 (98.7) 223 (97.4) 959 (97.2) 1566 (97.6) 
Smoking, n 
(%) 
   0.00  
Yes 21 (5.4) 57 (24.9) 215 (21.8) 293 (18.3) 
No 12 (3.1) 5 (2.2) 20 (2.0) 37 (2.3) 
Unknown 356 (91.3) 167 (72.9) 752 (76.2) 1275 (79.4) 
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HAART*    n/a  
Yes 74 (19.0)   - 1 (0.1) n/a 
No 2 (0.5)   -    - n/a 
Unknown 
N/A 
313 (80.5) 
   - 
8 (3.5) 
221 (96.5) 
980 (99.7) 
2 (0.2) 
n/a 
CD 4 count    n/a  
<200 124 (31.9) n/a n/a n/a 
>200 78 (20.1) n/a n/a n/a 
Viral load    n/a  
Present 106 (27.2) n/a n/a n/a 
Not detected 5 (1.3) n/a n/a n/a 
Unknown 278 (71.5) n/a n/a n/a 
*Missing data 
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4.1.1: Distribution of head and neck cancer by gender  
As illustrated in Figure 1 below, more females (60.8%) than males (39.2%) were diagnosed 
with head and neck cancer between 2009 and 2013.                   
           
 
                    Figure 1: Gender distribution of all patients diagnosed with HNC 
 
 
When the patients diagnosed with HNC were grouped according to their HIV status, more 
females (52.3%) were confirmed as HIV-positive whilst most males (64.6%) were HIV-
negative in this cohort as shown in Figure 2 below. 
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Figure 2: Gender distribution of cases with HNC in relation to their HIV status 
 
 
 
OSCC was diagnosed in (77.3%) of females and (19.8%) of males. Among patients with KS 
diagnosis, (35.7%) were males and (0.4%) were females. NHL diagnosis was in (34.2%) 
males, and (2.2%) female patients, HL in (2.6%) males and (2.6%) females, SGTs in (1.0%) 
males and (2.2%) females and other types of HNCs in (6.7%) males and only (15.3%) female 
patients as Figure 3 depicts below. 
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           Figure 3: Categories of HNC in relation to the gender of all patients included in this 
           cohort                                                      
 
 
Figure 4 below illustrates the HNC diagnosis in relation to the gender of HIV-infected 
patients. Kaposi sarcoma was diagnosed in (42.4%) of female patients and (28.2%) of male 
patients, NHL (34.0%) female patients and (37.3%) male patients and OSCC (12.3%) female 
patients and (28.1%) male patients. 
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Figure 4: Categories of HNC related to the gender of HIV- positive cases 
 
 
 
4.1.2: Distribution of head and neck cancer diagnosis by age 
  
The largest number of the participants (45.3%) in the study was aged between 46 and 65 
years, with the least number (16.5%) aged between 36 – 45 years as depicted in Figure 5. The 
results also indicated that 18.6% of the patients diagnosed with HNC were ≤ 35 years and 
19.6% were ≥ 66 years. 
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                          Figure 5: Age distribution of patients diagnosed with HNC 
 
  
Figure 6 demonstrates that the age groups of patients affected with HIV, those without HIV- 
infection and the unknown category. In the age group of ≤ 35 years, 24.1% of the patients 
were HIV- positive, 15.3% HIV- negative and 60.6% of cases having an unknown status. 
From 36 – 45 years of age, 24.1% were HIV- positive, 12.6% HIV- negative and 63.3% 
unknown. For the age group of 46 - 55 years, 25% were HIV- positive, 14.3% HIV- negative 
and 60.7% unknown. Above 55 years of age to 65 years 22.6% of the patients were HIV- 
positive, 12.4% HIV-negative and 63% unknown. For those ≥ 66 years old, 24.8% were HIV-
positive, 14.7% were HIV- negative and 60.5% were unknown cases. The highest number of 
HIV-positive cases was in the 46 – 55 year age group. 
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                Figure 6: Age distribution of the patients in relation to their HIV status 
 
 
Of  the 139 diagnosed cases of KS, more than half (78) of them were in the age group of ≤ 35 
years, with 45 of the cases in the 36 – 45 years age group, 13 in the 46 – 55 years age group 
and only 3 cases in the group 56 – 65 years of age. No KS was diagnosed in the age group ≥ 
66 years. NHL was the second highest HNC diagnosed among HIV-positive cases, with 60 of 
them seen in the ≤ 35 years age group, 58 in the 36 – 45 years age group, 13 in the 46 – 55 
years age group, 6 in the 56 – 65 years age group and only one case in the age group ≥ 66 
years. OSCC had 29 cases in the age group 46 – 55 years, 23 in the 36 – 45 years age group, 
15 in the 56 – 65 years and 8 in the ≤ 35 years age group. Only 2 cases were in the age group 
≥ 66 years as illustrated in Figure 7 below.  
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              Figure 7: HNC diagnosis in HIV-positive patients with respect to age 
 
 
 
4.2: Types of head and neck cancers (HNC) occurring among HIV-infected patients 
 
The most common HNC diagnosed amongst HIV- positive people in this study was KS (35, 
7%) and NHL (34, 2%), followed by OSCC (19, 8%) as shown in Table 3. KS was also 
diagnosed in 0.4% of the HIV- negative cases, NHL in 2.2% and OSCC in 77.3%. The 
unknown category had 5.8% of KS cases, 7.9% NHL and 62.3% OSCC cases. HL was 
diagnosed in 2.6% of HIV- positive cases, 2.6% HIV- negative and 2.2% unknown cases. 
Salivary gland tumours (SGT) were diagnosed in 1.0% of HIV- positive cases, 2.2% HIV- 
negative and 2.0% unknown cases. An illustration to compare the distribution of the three 
most common head and neck cancer diagnosed in relation to HIV status is shown in Figure 8.  
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Table 3: Head and neck cancer diagnosis in relation to HIV status 
 HIV + HIV - Unknown 
HNC diagnosis n % n % n % 
OSCC 77 19.8 177 77.3 616 62.3 
KS 139 35.7 1 0.4 57 5.8 
NHL 133 34.2 5 2.2 78 7.9 
HL 10 2.6 6 2.6 22 2.2 
SGT 4 1.0 5 2.2 20 2.0 
Others  26 6.7 35 15.3 195 19.7 
    TOTAL                             389                            229                              988                                                                           
 
   
 
 
                   Figure 8: Categories related to HIV status 
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HIV+ 19.8% 35.7% 34.2% 2.6% 1% 6.7%
HIV- 77.3% 0.4% 2.2% 2.6% 2.2% 15.3%
Unknown 62.3% 5.8% 7.9% 2.2% 2.0% 19.7%
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4.2.1: Head and neck cancer diagnosis and anatomical site predilection in all recorded 
patients 
 
The oral cavity was the most common anatomical site for head and neck cancer diagnosis at 
(16.4%) followed by the larynx (15.3%), the tongue (11.3%) and jaws (11.2%). The palate 
(10.3%), neck (9.9%) and the nasal cavity (7.5%) were not far behind as shown in Figure 9 
below followed by the lips (5.3%), the pharynx (4.6%), salivary glands (2.3%), ears (2.1%), 
the forehead (0.1%). Some of the HNCs diagnosed were affecting multiple sites in some 
individuals (2.6%). In 0.8% of the cases the anatomical site was not specified.  
 
 
Figure 9: Anatomical distribution of HNC diagnosed in this cohort 
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Figure 10 below depicts the anatomical site predilection only in patients infected with HIV. 
The larynx was the main anatomical site that the HNCs were diagnosed in at 19.2%, followed 
by the palate at 16.5%, tongue 15.7%, oral cavity 14.7%, neck 14.1%, jaws 6.6%, pharynx 
6.2%, lips 2.8%, nasal cavity 2.1%, salivary glands 1.3%, ear 0.5% and 0.3% of multiple 
sites. 
 
 
Figure 10: Anatomical distribution of HNC among HIV-positive cases 
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4.3: Head and neck cancer diagnosis and HAART/ARV therapy in HIV infected 
patients 
Some of the cases diagnosed with HNC were already receiving highly active antiretroviral 
therapy. Thirty-three cases that were HIV-positive with KS were already receiving HAART 
and 25 cases with NHL. Of the 77 patients with OSCC, 8 were already on HAART. For all 
the other types of HNCs, 4 of the patients were on HAART and 4 with HL, as illustrated in 
Figure 11. 
 
 
               Figure 11: Categories of HNC in relation to HAART/ART use  
               (N = 74) 
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4.4: Association of head and neck cancer diagnosis with the HIV status of the patients 
 
The association between cancer diagnosis and HIV status was analysed using multinomial 
logistic regression. Multivariate regression was done and adjusted for age and gender. 
Univariate multinomial regression analysis of the morphological type of cancer showed that 
patients infected with HIV were significantly more likely, 187.1 and 35.8 times, to be 
diagnosed with KS and NHL respectively, than patients without HIV infection as shown in 
Table 4 below. OSCC, HL and salivary gland tumours showed no significant difference in 
patients with or without HIV. 
 
 
Table 4: Association between cancer diagnosis and HIV infection 
 Univariate Multivariate 
Diagnosis OR 95%CI p OR 95%CI p 
OSCC 0.59 0.33-1.04 0.07 0.76 0.42-1.38 0.37 
KS 187.12 24.54-1426.71 0.00 130.2 16.6-1023.6 0.00 
NHL 35.81 12.82-100 0.00 25.0 8.9-71.2 0.00 
HL 2.24 0.72-6.96 0.16 1.94 0.56-6.7 0.29 
Salivary gland 
tumour 
1.08 0.26-4.41 0.92 0.69 0.16-2.92 0.62 
Multivariate regression analysis was adjusted for age and gender 
Reference category was HIV- negative cases 
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4.5 Association between head and neck cancer diagnosis and CD4+T-cell count 
 
Also, multinomial regression analysis of cancer diagnosis showed a significant association 
with CD4+T-cell count in KS and NHL. The odds of a diagnosis of KS and NHL in HIV-
positive patients with CD4+T-cell count greater than 200 was increased by 0.19 and 0.25 
respectively when compared with people with CD4+T-cell count less than 200 as shown in 
Table 5 (p=0.05).  
 
 
 
Table 5: Association between cancer diagnosis and CD4+ count 
 Univariate Multivariate 
Diagnosis OR 95%CI p OR 95%CI p 
OSCC 1.58 0.63-3.92 0.33 1.55 0.59-4.04 0.37 
KS 0.19 0.08-0.49 0.00 0.15 0.07-0.48 0.00 
NHL 0.25 0.10-0.60 0.00 0.27 0.11-0.69 0.01 
Others - - - 0.78 0.42-1.38 0.36 
Multivariate regression analysis was adjusted for age and gender 
Reference category CD4+T-cell count of  less than 200 
 
 
 
 
 
 
28 
 
CHAPTER 5: DISCUSSION 
 
This study was aimed at determining the types of head and neck cancer seen in patients 
infected with the human immunodeficiency virus. The demographic profile of the HIV- 
positive patients was determined and analysed as well as the confirmatory HIV blood test 
results, CD4+ T-cell count as well as the RNA viral load from the NHLS records. 
 
5.1: Demographic profile 
 
A total of 1605 cases of head and neck cancer were recorded at the WOHC between 2009 and 
2013. Only (389 = 24.2%) of the total sampled was confirmed HIV- positive cases. The rest 
were either HIV- negative (14.3%) or unconfirmed (61.5%) cases, even after an extensive 
search from the NHLS database. HIV- infection was mainly found among Black South 
African patients (91.5%). The reasons for the excess number of cases with an unknown HIV 
status are multifactorial; one of them being the lack of proper medical details of patients 
provided by the clinicians when requesting for histological analysis of lesions.  Some people 
also would rather go to the private sector or a public health facility outside of their respective 
provinces so as to remain anonymous and avoid stigmatization by the community (Snow et 
al, 2010). Another possible reason is that older men and women are less likely to go to clinics 
and get tested for HIV- infection and will only do so after they become symptomatic and 
have received a referral from a health professional (Sengayi et al, 2015). Socio-economic 
factors also play a big role as the level of education and proper knowledge about HIV- 
infection are important factors in so far as whether an individual is more likely to come forth 
and get tested or not (Vankatesh et al, 2011). Young men and women who completed high 
school or tertiary education usually seek HIV testing voluntarily because they had received 
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information about the virus before (Tabana et al, 2012). McPhail et al, (2009) also counted 
urban residence as an independent correlate for HIV testing among sexually experienced 
women.  
More females (52.3%) were confirmed to be infected with HIV than males (47.7%) in this 
study. This high prevalence observed  in women was the same as that reported in a couple of 
other cohort studies conducted here in South Africa by  Sitas et al, (2000),  Stein et al, 
(2008), Snow et al, (2010), Tabana et al, (2012) and Sengayi et al, (2015). One of the reasons 
for this has been said to be possible because women generally have a higher uptake of the 
free HIV counselling and testing (HCT) offered at state facilities, especially those of child-
bearing age (15 – 49 years) (Tabana et al, 2012).  Males on the other hand usually have very 
limited health care visits and therefore are not tested for HIV- infection as often as their 
female counterparts (MacPhail et al, 2009; Snow et al, 2010; Sengayi et al, 2015). McPhail et 
al, (2009) also suggests that men are more likely to present themselves for HIV testing only 
after developing symptoms associated with the disease. 
The age group of subjects diagnosed with HIV- infection was mainly young adults, mainly 
between the ages 36 – 55 or younger than 35 years. In many other studies conducted here in 
South Africa, the age range is the same as the one observed in this study. Many reasons have 
been cited for this, for example; “a higher level of education, residing in an urban area vs. 
rural area and the fact that most females at this age range are in committed relationships and 
at child-bearing age and are frequently attending ante-natal clinics (ANC) and therefore are 
getting screened for HIV- infection regularly” (Peltzer et al, 2009; MacPhail et al, 2009). 
Poverty also plays an important role especially when it comes to young women contracting 
the disease because of sexual interaction with older men in exchange for monetary gain and 
also the fact that women are biologically more susceptible to HIV- infection (Pettifor et al, 
2007; Williams et al, 2000). 
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 Alcohol use and smoking were mostly unknown in this cohort, 97.6% and 79.4% 
respectively. This was mainly because of the missing information regarding smoking or 
alcohol consumption for the subjects on the histological request forms provided by respective 
clinicians and since this was a retrospective study, verification of the missing information 
was not possible. It is however a well-known fact that tobacco smoking and alcohol 
consumption is rife among HIV- infected individuals, because of the high levels of stress and 
depression experienced by these individuals after they find out about their status (Grulich AE, 
2009).  Kalichman et al, (2007) reported that alcohol ingestion was associated with a high 
risk of contracting HIV or sexually transmitted infections (STI) in South Africa because of 
the resultant risky sexual behaviour by these individuals. Men were found to drink more than 
their female partners leading to an increased risk for the women to contract sexually 
transmitted infections including HIV because of the risky behaviour (Kalichman et al, 2007). 
 
5.2: Head and neck cancer diagnosis in relation to the HIV status of patients 
 
More females were diagnosed with HNC in this cohort at 52.3% than males at 47.7%. The 
mean age of the subjects was 51.7 ± 16.4 years. Most of them were between ages 46 – ≥ 66. 
When the subjects diagnosed with HNC were grouped according to their HIV status; females 
showed a higher prevalence of HNC in the HIV- positive group than males. The HIV-
negative and unknown groups showed a higher prevalence of HNC among males. 
Kaposi sarcoma (35.7%), non-Hodgkin’s lymphoma (34.2%) and oral squamous cell 
carcinoma (19.8%) were the most diagnosed cancers among HIV-positive cases in this 
cohort. The results of this current study are similar to results of other studies carried out 
previously in Sub-Saharan Africa, where elevated risks for KS and NHL were determined 
among individuals diagnosed with HIV (Sitas et al, 2000; Stein et al, 2000; Newton et al, 
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2000; Mbulaiteye et al, 2006). These types of cancers are often associated with co-infections 
of oncogenic viruses; human herpes virus (HHV-8) for KS and Epstein-Barr virus (EBV) for 
NHL (Baker et al, 2008). NADC’s are mostly associated with lifestyle factors like smoking, 
alcohol consumption and related viral infections in HIV-infected people for example; human 
papilloma virus (HPV) for oropharyngeal squamous cell carcinoma and smoking 
habit/alcohol consumption for oral squamous cell carcinoma (Mbulaiteye et al, 2003). 
 
5.2.1: Kaposi sarcoma (KS) 
 
Kaposi sarcoma was common in sub-Saharan Africa and South Africa even before HIV was 
discovered, and to a lesser extent was also seen in the Mediterranean countries like Italy, 
Greece and the Middle East (Sitas et al, 2000). The incidence in South Africa increased 
almost threefold between 1988 and 1996 and continued to rise as the HIV epidemic was 
growing (Sitas et al, 2000). Nowadays, KS is strongly associated with HIV (Sasco et al, 
2010). Studies conducted in South Africa and Rwanda found a definitive association between 
HIV infection and KS with Odds Ratios (ORs) ranging from 21.9 to 47.1 (Mbulaiteye et al, 
2006). KS is one of the AIDS-defining-cancer, according to the 1993 Centers for Disease 
Control classification (CDCC). 
In the current study KS was found more in females than males (42.4%: 28.2%), (OR = 130.2; 
95% CI 16.6 – 1023.6).  These results differ somewhat with results found in other studies in 
SA and Zimbabwe where the incidence of KS was higher among males than females (Sitas et 
al, 2000; Sasco et al, 2010).  In a Ugandan record linkage study the incidence for KS among 
HIV infected individuals was found to be the same for both males and females (Mbulaiteye et 
al, 2006). The reasons for the difference in the incidence of KS and the gender of infected 
individuals is not fully understood as yet, especially because the prevalence of the causative 
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factor HHV-8, is the same in both males and females (Sitas et al, 2000). In sub-Saharan 
Africa, HHV-8 sero-prevalence is very high among the population and its prevalence 
increases the older the infected individual becomes, suggesting that infection with the virus in 
most of these individuals is not really a new one or sexually transmitted as is the case in the 
United States (Sitas et al, 2000). Mbulaiteye (2003) stated how this virus (HHV-8) is readily 
detected in saliva more than in genital secretions of infected people in Africa and suggested 
horizontal transmission of the virus through saliva between families. Anti-HHV-8 antibodies 
were also detected in infants of mothers confirmed to be HHV-8 seropositive in a study 
conducted in rural South Africa suggesting vertical transmission from mother to child as 
another reason for the high prevalence of the virus in Africa (Wilkinson et al, 1999). The low 
prevalence of HHV- 8 infection observed in white males with higher levels of education 
when compared to a  high one observed among black males with lower levels of education in 
South Africa, also implicates poverty related factors as another reason for the high prevalence 
of the virus (Sitas et al, 2000). However, this is in complete contrast to the findings in 
Uganda where infection with HHV-8 is associated with better education and wealth among 
black males (Wabinga et al, 1993). He also found a low incidence (<7%) of KS among those 
also infected with HIV in the same study.  
Kaposi sarcoma is strongly linked with immunodeficiency, the lower the CD4+ cell count, 
the higher the risk of developing KS, although the risk is still raised even in well preserved 
cell counts (Grulich AE, 2009). HHV-8 alone does not cause KS as immunosuppression in 
the particular individual is also necessary for carcinogenesis to occur (Mbulaiteye et al, 
2008). Results from the current study showed that the odds (OR) of an HIV- positive 
individual being diagnosed with KS were increased by 0.19 with a CD4+ T-cell counts of > 
200 cells/mm³ compared to those with lower counts. A study done by Mosam et al, (2008) in 
KZN SA, supports this as their results showed that 21% of the patients diagnosed with KS  
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had CD4+ T-cell levels of  >350 cells/mm³.  The reason behind this is not clearly understood, 
but unlike in the USA where KS is associated with a declining CD4+ cell count, in Africa 
this is not necessarily true. Mosam et al, (2008) suggested that maybe a severe immune 
suppression is not really required for the development of KS in African populations infected 
with HIV because of the age at which the infection with HHV8 occurs. In 2007, Maurer et al. 
reported on nine HIV- positive cases in San Fransisco, who were on HAART with CD4+T-
cell counts of >300 cells/mm³ that had persistent KS. The drug regimen they were taking 
consisted of a protease inhibitor, known to have antitumorigenic as well as antiangiogenic 
effects yet KS wasn’t resolving. The high number of aging HIV- positive patient also infected 
with HHV-8 was suggested as another possible reason for this enigma in their cohort.  In 
Sub-Saharan Africa HAART roll-out did not happen immediately after the discovery of HIV 
and AIDS and hence people infected with the virus did not have the ‘opportunity’ of 
developing KS as they did not live long enough (Mbulaiteye et al, 2006). Mbulaiteye et al 
(2003) also proposed that the contradicting evidence in regard to HHV-8 seropositivity and 
the incidence of KS that is experienced in Africa is possibly because of differences in the 
distribution of unknown infective cofactors or inadequate assay performances conducted. 
After the introduction of HAART in resource-rich countries, KS cases declined immediately 
(Mbulaiteye et al, 2003). In South Africa, the prevalence of KS is still high even after the 
introduction of HAART in 2004 to HIV- positive people by the government as demonstrated 
in a few studies like those of Sitas et al in 2000 and Sasco et al in 2010. The results of the 
present study also support this as KS was the highest diagnosed cancers (35.7%) among HIV-
infected people. The possible explanation for this increased incidence might be the fact that 
HIV infection is still a highly stigmatised disease in South Africa as well as other countries in 
Africa and patients are too scared to present themselves to clinics to receive HAART as they 
do not want people to know of their positive status or the type (protease inhibitor or 
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nucleoside analogue reverse transcriptase) of HAART regimen they are receiving.  Another 
explanation might be due to immune reconstitution inflammatory syndrome (IRIS) following 
HAART as natural killer and cytotoxic T-lymphocyte activity increases (Bower et al, 2005). 
Only 33 out of 139 patients diagnosed with KS in this study were already on HAART as 
illustrated in Figure 11, we could not conclude whether this was IRIS- related KS or not as 
we failed to determine the exact time frame between the diagnosis of KS, CD4 T-cell count, 
viral load levels and the introduction of HAART in an individual. The type of HAART 
regimen the subjects were receiving could also not be determined.   
 
5.2.2: Non-Hodgkin’s Lymphoma (NHL) 
 
NHL is the second most common cancer associated with HIV infection (ECC, 1999). The 
results of the current study also show that NHL was the second highest cancer diagnosed 
among HIV-infected cases (34.2%). Risk factors for development of NHL are poorly 
understood but absolute risk develops with age and it’s higher in men and white people 
(Mbulaiteye et al, 2003). In people living with HIV the risk of developing NHL is even 
greater compared to that of the general public and it increases with the duration of infection 
(Mbulaiteye et al, 2003). NHL is generally associated with both congenital and medically 
related immunosuppression and hence the association with HIV (L. Dal Maso et al, 2001, 
Bower et al, 2005). In a study conducted by Bower et al, (2005) three factors were identified 
that were significantly associated with the development of NHL namely; the age of the 
individual, CD4+ T-cell count and no prior received HAART, supporting the association of 
NHL with a suppressed immune system. 
Similar findings have been confirmed in several other studies conducted in SA and sub-
Saharan Africa before. Studies conducted by Sitas et al, (1997) and (2000) in Johannesburg, 
35 
 
South Africa found a strong association between HIV and NHL (OR = 5.0, 95%, CI = 2.7-
9.5).   Lymphoma cases (37%) studied in the Tygerberg area of the Western Cape, SA from 
2002-2009 were reported to be related to HIV- infection, which was a significantly high 
increase of 6% in 2002 (Abayomi et al, 2011). Stein et al (2008) reported a six-fold higher 
risk of NHL in HIV infected individuals in Johannesburg, South Africa. Another increased 
risk for the development of NHL among HIV infected individuals was reported in a study 
conducted in central Africa (Newton et al, 2000). In Uganda, NHL standardized incident 
ratios (SIR) were increased 6.7 times (95% CI, 1.8-17) compared to the general population, in 
a HIV/AIDS-cancer match study (Mbulaiteye et al, 2006). 
The risk for NHL in people infected with HIV was relatively low in Kampala, Uganda, which 
is a resource-poor area compared to the high risk demonstrated in resource-rich countries 
(Parkin et al, 2000). Engels et al (2006) reported the risk for NHL among people with AIDS 
in the US decreased by 57.5% (SIR, 53.2 during the period 1990-95 and 22.6 during 1996-
2002; P<0.0001) compared to that of the general population. Mbulaiteye et al (2011) stated 
that the reasons for this difference in risk between Africa and the Western countries could be 
artefactual due to under-diagnosis, mortality or environmental factors experienced in 
resource-limited settings. Patients with severe immunosuppression usually die from other 
infectious diseases (tuberculosis and malaria) in Africa before they develop NHL, making 
this another possible reason for the low prevalence (Parkin et al, 2000; L. Dal Maso et al, 
2001). EBV is usually acquired early in childhood in Africa resulting in a declined lymphoma 
risk following immunosuppression and reactivation of the virus in HIV-infected individuals 
later on in life, which is another possible reason behind the differences experienced between 
resource-rich and poor countries (L. Dal Maso et al, 2001).  
NHL was diagnosed more in males than females in this study (37.3%:34.0%). In Western 
Europe NHL was reported to be highest among males, homosexual and bisexual men (L. Dal 
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Maso et al, 2001). It was also seen more in the ≤ 35 and 36 - 45 years age groups. Tanon et 
al, (2012) reported from a study conducted in West Africa that NHL was diagnosed at the 
median age of 41.5 years in HIV-positive cases; this is within the same age range as found in 
this study.  
Of the 133 cases diagnosed with NHL, 25 were already on HAART. The OR for NHL 
diagnosis in a HIV-infected subject with a higher CD4+T-cell count (>200 cells) was 
increased by 0.25 in the current study. The reason behind the failure of HAART in decreasing 
the incidence of NHL in an African setting is not clearly understood. Casper (2011) 
conducted a review on the increasing burden of cancer in resource-poor countries and 
suggested; 1) the lack of sufficient HAART coverage in the population at risk for cancer, 2) 
the type of HAART regimen provided or available in resource-poor countries and 3) the 
higher prevalence of oncogenic viruses in these settings, as possible reasons for the reduced 
impact that HAART has had in decreasing rates of NHL and KS in Africa. 
 
5.2.3: Oral Squamous Cell carcinoma (OSCC) 
 
The EC-Clearinghouse classification in 1993 classified OSCC as one of the neoplasms 
strongly associated with HIV. Shiboski et al (2009) also included OSCC in their case 
definitions as one of the neoplasms strongly associated with HIV. The risk factors for 
developing OSCC among HIV infected individuals and the general population is the same 
though and hence OSCC was never considered an ADC because of this reason (D’Souza et 
al, 2014). OSCC was the third most common cancer diagnosed among HIV- positive people 
at 19.8% in this study, but there was no significant correlation between its diagnosis and 
CD4+T- cell count levels. It was diagnosed more among males (28.1%) than females (12.3%) 
and in older age groups of ≥45 years and above.  
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Pro-oncogenic virus-related and tobacco or alcohol-related cancers are common among HIV 
infected individuals because of the impaired immune surveillance as CD4+T- cell count 
becomes depleted (Baker et al, 2008, Silverberg et al, 2011, Franzetti et al, 2013). Recently 
an increase in HPV-related oropharyngeal cancers has been noted in AIDS cancer registry 
studies as well as cohort studies (Frisch et al, 2000, Clifford et al, 2005, Chartuvedi et al, 
2008 and 2009). HPV-16, the oncogenic type of HPV family, is highly prevalent in HIV 
infected people at 2 – 7% (Beachler et al, 2012). HPV persistence is also increased among 
immunosuppressed individuals (D’Souza et al, 2014). There is also increased usage of 
tobacco and alcohol among HIV infected people because of the high stress levels these 
individuals are subjected to and also sexual risk factors making them more prone to develop 
oropharyngeal cancer (Silverberg et al, 2011, D’Souza et al, 2014). The fact that HIV 
infected people are now also living longer because of HAART implies that the risk for cancer 
development increases even more. Which one of these factors explains the risk increase 
exactly more than the other is still unclear (D’Souza et al, 2014).   
In the current study it is not clear how many of the OSCC cases were HPV-related and 
whether all had a history of tobacco or alcohol usage due to missing information in the 
archives. Only 5.4% of the HIV-infected individuals had a confirmed history of smoking and 
only 0.8% of alcohol ingestion before diagnosis with HNC.  Ninety-one point three percent 
and 98.7% of HIV- infected people had an unknown history of tobacco or alcohol usage 
respectively making it difficult to draw conclusions on how much of the OSCC cases were 
associated with the habits.  Gilyoma et al (2015) reported a 76.6% association between HNC, 
HIV infection and a history of smoking and alcohol consumption in his cohort. HPV testing 
for oropharyngeal cancers is not done routinely in our hospital because of the cost 
implications, similar to Gilyoma et al, 2015 study and therefore, it is not reported on in our 
study.   
38 
 
5.3: Head and neck cancer diagnosis in relation to anatomical site predilection 
 
The most involved site for HNC in HIV- positive individuals was the larynx (19.2%) 
followed by the palate (16.5%) and the tongue (15.7%). The oral cavity (14.7%) and the neck 
(14.1%) were not far behind. Only (5.4%) of the HIV- infected individuals had a confirmed 
history of smoking and only (0.8%) of alcohol ingestion before diagnosis with HNC. Thirty-
seven percent of the cancers observed in Bugando medical centre, Tanzania, occurred in the 
oral cavity followed by the pharynx (16.2%) and the larynx (13.9%) in HIV- infected people 
between January 2009 and December 2013 (Gilyoma et al, 2015). The oral cavity was the 
most involved site in Gilyoma’s study which differs slightly with our study, where the larynx 
was the most affected site. Amusa et al, (2004) also reported the oral cavity (36.8%) as the 
most common site for HNC in a study conducted in Nigeria. A study done in Sub-Saharan 
Africa in 2007 on the prevalence of HNC among HIV seropositive people found laryngeal 
cancers as the most common HNCs (31.3%), with (15.0%) of patients having a history of 
smoking and alcohol ingestion (Nwaorgu et al, 2007). SGTs were the most common cancers 
associated with HIV infection (40%) in their study, whereas in the current study only 1% of 
SGTs were found among HIV-positive patients. This is contrary to a study done by Tanon et 
al (2012) in West Africa where the oral cavity, pharynx and larynx only represented 9.7% of 
HNCs in HIV- infected people. Sitas et al (2000) in a study conducted in South Africa only 
found 5.4% of laryngeal cancers among HIV infected individuals. In Kenya, the larynx was 
reported as the most common site for HNC followed by the tongue (Onyango et al, 2006), 
similar to the findings of the current study. 
There is a definite difference in the anatomical sites that exists from all studies that have been 
conducted in different regions, but the reasons for this are not clearly understood. 
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Geographical location as well as socio-cultural practices that exist among people from these 
regions might be some of the reasons for these differences (Gilyoma et al, 2015). 
 
5.4: Head and neck cancer and HAART/ARV therapy 
  
KS and NHL are known as ADCs and the risk and severity of the two cancers increases 
greatly as the CD4 cell count decreases and HIV infection progresses in an individual 
infected with the virus (Mbulaiteye et al, 2003). Silverberg et al (2015) reported HIV RNA 
levels to be closely associated with an increased risk of KS and NHL in a study conducted in 
California, but not for other type of cancers. It still remains unclear exactly how depressed 
immunity increases the risk for cancer development in HIV infected people (Barbaro et al, 
2007). Besides immunosuppression, several other mechanisms are thought to be contributing 
to cancer development e.g. infection by oncogenic viruses and imbalance between cellular 
proliferation and differentiation (Barbaro et al, 2007). In the Western countries, the 
introduction of HAART resulted in significant decline in KS rates and a modest decline with 
NHL rates but not with other types of cancer (Int. Coll. Cancer and HIV, 2000). In resource-
limited countries, KS and NHL rates are still very high even after the introduction of HAART 
(Mbulaiteye et al, 2006, Stein et al, 2008, Casper, 2011). 
In this study KS and NHL were the two most common cancers to be diagnosed in people that 
have HIV infection (OR = 187.1, 95% CI:  24.5 – 1426.7; OR = 35.8, 95% CI: 12.8 – 100 
respectively). The odds of a diagnosis of KS and NHL in HIV infected subjects with CD4 
cell count > 200 cells/mm³ was increased by 0.19 and 0.25 respectively when compared with 
people with CD4+T-cell count < 200 cells/mm³. Higher levels of CD4 T-cell count have been 
reported previously in African studies as well (Morgan et al, 2000, Mosam et al, 2005 and 
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2008). This then supports the idea that immunosuppression in an African setting is not a 
prerequisite for the development of KS (Mosam et al, 2005). 
 
5.5: Limitations of the study 
 
 Some of the cases (61.4%) with a histologic diagnosis of head and neck cancer at the 
Oral Pathology Department, WOHC, did not have confirmed positive serologic results 
for HIV infection both on the departmental records and the NHLS archives and this 
made it difficult to draw conclusive correlations between the type of HNC diagnosed 
and the HIV status of the cases.  
 Whether there was a time lag between the histologic diagnoses of the HNC and the 
tests/results for CD4+ T cell count and the RNA viral load or not remains unknown. 
This could not be verified due to a lack of information and proper record keeping and 
linkage from both of the utilised archives (Oral pathology and NHLS) in the study. 
Therefore, the correlations/associations between the time of HNC diagnoses and the 
patient’s immune status and the level of infection might not be a true reflection.  
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5.6: Conclusion 
 
The aim of the study was to identify and characterise the types of histologically diagnosed 
HNCs occurring among HIV-infected people. The results of the study indicated Kaposi 
sarcoma and Non-Hodgkin’s lymphoma, both confirmed AIDS-defining cancers (ADCs), as 
the two most commonly occurring HNCs among HIV-infected cases. The third most common 
cancer seen among the HIV infected cases was oral squamous cell carcinoma, a non-AIDS 
defining cancer (NADC). Only 2.6% of the HIV-infected cases were diagnosed with 
Hodgkin’s lymphoma and only 1.0% with salivary gland tumours, both NADCs. From this it 
is clear that the incidence of KS and NHL among HIV-positive people is still high, despite 
the roll-out of HAART in April 2004 by the South African government to people with 
CD4+T-cell counts of < 200 cells/mm³.                        
A correlation was found between HIV infection, a CD4+ T-cell count of >200 cells/mm³ and 
development of KS and NHL (OR of 0.19 and 0.25 respectively). Thirty-three of the HIV-
positive patients diagnosed with KS and 25 diagnosed with NHL were already receiving 
HAART. Whether this could be attributed to the effects of a possible immune reconstitution 
inflammatory syndrome (IRIS) or HAART failure is unclear. The type of HAART regimen 
and the level of infection (CD4+T-cell count and RNA viral load count) of the patients at the 
time when they started with HAART could not be verified leading to inconclusive results. 
More studies need to be conducted here in SA to determine why KS and NHL incidence is 
not decreasing in our country despite HAART being freely available to HIV- positive people 
from government institutions. Better surveillance systems as well as population-based cancer 
registries are vital for this to happen and should be integrated with established HIV programs 
in South Africa and sub-Saharan Africa as a whole. This will assist tremendously with future 
studies in this particular field and will result in proper coordinated approach and improve the 
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quality of services aimed at controlling and reducing the ever increasing number of cancer 
cases and resultant deaths among HIV-infected people.  
Sub-Saharan Africa still has the highest number of people infected with HIV and South 
Africa still experiences high numbers of new infections yearly, especially among female 
teenagers. This is affecting the economic growth of the country negatively because of high 
morbidity and mortality rates among the working class resulting in skill shortages and job 
losses. This also places a huge burden on the health systems of the country, and hence the 
need for improved disease control and management thereof. 
 In June of 2015 a decision was announced during the 7
th
 South African AIDS conference 
held in the city of Durban, to start HAART immediately in people diagnosed with HIV 
infection, irrespective of the CD4+T-cell count. This new policy was implemented in 
September 2016 (UNAIDS, 2016). This is aimed at improving the quality of life for HIV- 
infected people and hopefully decrease the morbidity and mortality rates that the country is 
experiencing. Prospective studies should be conducted to determine whether this new 
initiative will reduce the high incidence rates of ADCs as well as NADCs among HIV- 
positive people in the country and whether the quality of life is improved as expected or not. 
A number of research studies have been and are currently being conducted worldwide to try 
and develop a vaccine against the human immunodeficiency virus (HIV), to assist in curbing 
the number of new infections still occurring to this day. An HIV vaccine trial study was 
announced to be initiated in South Africa and is to be funded by the National Institute of 
Allergy and Infectious Diseases (NIAID) and its partners. This clinical trial (HVTN 702) will 
be conducted by the HIV Vaccine Trials Network (HVTN). This is to determine if the 
vaccine is effective in preventing HIV infection among South African adults or not and 
whether it is safe and tolerated by the participants involved in the study. The results are 
43 
 
expected in 2020. If successful, this will decrease the burden of HIV disease in populations 
with high rates of HIV infections like ours in South Africa (NIH news, 2016).  This vaccine 
study will thus be beneficial for future prospective studies to assess the impact of its use in 
decreasing the number of new HIV infections and the manifestations thereof.  
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APPENDICES 
Appendix A               
Num
ber 
Site of involvement Diagnosis including the date Age  Gender Ethnici
ty 
HIV 
status 
CD4+Tcell count 
+ date 
Viral load + 
date 
Histological grading of tumour Smoking and 
Alcohol 
1 
 
 
 
 
         
2. 
 
 
 
 
         
3 
 
 
 
 
         
4 
 
 
 
 
         
5  
 
 
         
6  
 
 
         
7  
 
 
         
8  
 
 
         
9  
 
 
         
10  
 
 
         
11  
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